Christophe Douat

Chief Executive Officer at MEDINCELL S.A.

Net worth: 7 M $ as of 2024-03-30

60 year

38 connections

Consumer Services

Health Technology

Finance

Profile

Christophe Douat is the founder and Chief Executive Officer of MedinCell SA, which was founded in 2003.
He is also the founder of Matignon Technologies II FCPR.
Currently, he holds the position of Chairman at Great North SARL and Director at CM Biomaterials BV.
In the past, he has held positions as Director-Stakes at Matignon Investissement et Gestion SAS from 2001 to 2010, Director at Arterial Remodelling Technologies SA, and Director at Groupement International d'Informatique de Santé SA. He was also a Member-Supervisory Board at Nanobiotix SA from 2011 to 2017 and from 2006 to 2009.
Additionally, he served as the General Manager at Sabourin Lake Lodge from 1992 to 1997 and as a Venture Partner at Matignon Technologies from 2001 to 2009.
Mr. Douat has a graduate degree from the University of Minnesota, an MBA from the University of Calgary, and an undergraduate degree from École Nationale Supérieure des Mines de Paris.
Mr. Douat is also the founder of Matignon Technologies II FCPR.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
MEDINCELL SA 2.25%	2023-03-30	652,916 ( 2.25% )	7 M $	2024-03-30

Christophe Douat active positions

Companies	Position	Start
MEDINCELL S.A.	Chief Executive Officer	2003-01-08
Great North SARL	Chairman	-
CM Biomaterials BV CM Biomaterials BV Miscellaneous ManufacturingProducer Manufacturing CM Biomaterials BV is a Dutch company that manufactures plastic products. The joint venture company is based in Gorinchem, Netherlands.	Director/Board Member	-

All active positions of Christophe Douat

Former positions of Christophe Douat

Companies	Position	End
NANOBIOTIX	Director/Board Member	2016-12-31
Matignon Investissement et Gestion SAS Matignon Investissement et Gestion SAS Investment ManagersFinance Matignon Investissement et Gestion SAS (MIG) is an independent management-owned private equity investment firm based in Paris. MIG was established in 1996 through a management buy-out of Acmer from Banque Worms, formerly part of AXA-UAP and acquired by Deutsche Bank AG in 2001. Following the acquisition, Acmer was delisted. MIG manages private equity and venture capital funds, both generalist and sector specific.	Private Equity Investor	2010-04-30
Matignon Technologies	Corporate Officer/Principal	2009-03-31
NANOBIOTIX	Director/Board Member	2008-12-31
Sabourin Lake Lodge	Corporate Officer/Principal	1996-12-31

See the detail of Christophe Douat's experience

Training of Christophe Douat

University of Minnesota	Graduate Degree
University of Calgary	Masters Business Admin
École Nationale Supérieure des Mines de Paris	Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Christophe Douat's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
NANOBIOTIX	Health Technology
MEDINCELL S.A.	Health Technology

Private companies	8
Matignon Investissement et Gestion SAS Matignon Investissement et Gestion SAS Investment ManagersFinance Matignon Investissement et Gestion SAS (MIG) is an independent management-owned private equity investment firm based in Paris. MIG was established in 1996 through a management buy-out of Acmer from Banque Worms, formerly part of AXA-UAP and acquired by Deutsche Bank AG in 2001. Following the acquisition, Acmer was delisted. MIG manages private equity and venture capital funds, both generalist and sector specific.	Finance
Matignon Technologies II FCPR Matignon Technologies II FCPR Investment ManagersFinance Matignon Technologies II FCPR invests in early to later-stage companies mostly located in France and the European Union. It focuses on companies in the medical field or in the information technology sectors with revenues below €50 million. It invests between €500,000 and €10 million from early stage to growth operations.	Finance
Arterial Remodelling Technologies SA Arterial Remodelling Technologies SA Pharmaceuticals: MajorHealth Technology Arterial Remodelling Technologies SA develops bioresorbable peripheral and coronary polymer stents. Its products includes ART PBS scaffold, procedure and Clinical data. The company was founded by Antoine Lafont, Michel Vert and J. Frederick Cornhill in 2001 and is headquartered in Paris, France.	Health Technology
Groupement International d'Informatique de Santé SA Groupement International d'Informatique de Santé SA Publishing: Books/MagazinesConsumer Services Groupement International d'Informatique de Santé SA engages in the management of an online health and nutrition portal. Its services include daily effectiveness index, weekly synthesis, dietitian consultation, LeDiet community, practical tools, and chef and LeDiet recipes. The company was founded on October 9, 1986 and is headquartered in Paris, France.	Consumer Services
Great North SARL
CM Biomaterials BV CM Biomaterials BV Miscellaneous ManufacturingProducer Manufacturing CM Biomaterials BV is a Dutch company that manufactures plastic products. The joint venture company is based in Gorinchem, Netherlands.	Producer Manufacturing
Sabourin Lake Lodge
Matignon Technologies